Answers are grounded in this paper and cite their sources.
To confirm dose selection and rationale of using the reduction of total immunoglobulin G (IgG) levels as a pharmacodynamic (PD) marker of noninferiority for subcutaneous (SC) efgartigimod PH20 (coformulated with recombinant human hyaluronidase PH20).
No takes yet. Share an insight, caveat, or question.
G et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: